{"id":36702,"date":"2025-07-04T16:40:27","date_gmt":"2025-07-04T08:40:27","guid":{"rendered":"https:\/\/flcube.com\/?p=36702"},"modified":"2025-07-04T16:40:28","modified_gmt":"2025-07-04T08:40:28","slug":"betta-pharmaceuticals-kangmeina-approved-by-nmpa-for-advanced-breast-cancer-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36702","title":{"rendered":"Betta Pharmaceuticals&#8217; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment"},"content":{"rendered":"\n<p>China-based Betta Pharmaceuticals Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/300558:SHE\">SHE: 300558<\/a>) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.<\/p>\n\n\n\n<p><strong>Mechanism of Action<\/strong><br>Tibremciclib is a novel, fully proprietary molecular entity developed by Betta Pharmaceuticals. It targets cyclin-dependent kinases 4\/6 (CDK4\/6), which are key regulators of cell cycle progression. The drug specifically binds to CDK4\/6 to inhibit kinase activity, blocking the cell cycle transition from G1 to S phase. This mechanism suppresses cancer cell proliferation and metastasis-related signaling pathways.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u9152\u77f3\u9178\u6cf0\u745e\u897f\u5229\u80f6\u56ca\u4e0a\u5e02\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u9152\u77f3\u9178\u6cf0\u745e\u897f\u5229\u80f6\u56ca\u4e0a\u5e02\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-be6f7412-3677-4749-bc5d-bfbac686c5da\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u9152\u77f3\u9178\u6cf0\u745e\u897f\u5229\u80f6\u56ca\u4e0a\u5e02\u7684\u516c\u544a.pdf\">\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u9152\u77f3\u9178\u6cf0\u745e\u897f\u5229\u80f6\u56ca\u4e0a\u5e02\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/\u8d1d\u8fbe\u836f\u4e1a\uff1a\u5173\u4e8e\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6\u9152\u77f3\u9178\u6cf0\u745e\u897f\u5229\u80f6\u56ca\u4e0a\u5e02\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-be6f7412-3677-4749-bc5d-bfbac686c5da\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36707,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[231,16,15,1030],"class_list":["post-36702","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-betta-pharmaceuticals","tag-cancer","tag-product-approvals","tag-she-300558"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Betta Pharmaceuticals&#039; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36702\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Betta Pharmaceuticals&#039; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36702\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T08:40:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T08:40:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Betta Pharmaceuticals&#8217; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment\",\"datePublished\":\"2025-07-04T08:40:27+00:00\",\"dateModified\":\"2025-07-04T08:40:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702\"},\"wordCount\":129,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0410.webp\",\"keywords\":[\"Betta Pharmaceuticals\",\"Cancer\",\"Product approvals\",\"SHE: 300558\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36702#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36702\",\"name\":\"Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0410.webp\",\"datePublished\":\"2025-07-04T08:40:27+00:00\",\"dateModified\":\"2025-07-04T08:40:28+00:00\",\"description\":\"China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36702\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0410.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0410.webp\",\"width\":1080,\"height\":608,\"caption\":\"Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36702#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Betta Pharmaceuticals&#8217; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36702","og_locale":"en_US","og_type":"article","og_title":"Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment","og_description":"China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.","og_url":"https:\/\/flcube.com\/?p=36702","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T08:40:27+00:00","article_modified_time":"2025-07-04T08:40:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36702#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36702"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Betta Pharmaceuticals&#8217; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment","datePublished":"2025-07-04T08:40:27+00:00","dateModified":"2025-07-04T08:40:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36702"},"wordCount":129,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36702#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp","keywords":["Betta Pharmaceuticals","Cancer","Product approvals","SHE: 300558"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36702#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36702","url":"https:\/\/flcube.com\/?p=36702","name":"Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36702#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36702#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp","datePublished":"2025-07-04T08:40:27+00:00","dateModified":"2025-07-04T08:40:28+00:00","description":"China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36702#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36702"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36702#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp","width":1080,"height":608,"caption":"Betta Pharmaceuticals' Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36702#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Betta Pharmaceuticals&#8217; Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0410.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36702"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36702\/revisions"}],"predecessor-version":[{"id":36708,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36702\/revisions\/36708"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36707"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}